Statistics
The Outlook Therapeutics stock price is currently $ 0.4130 with a total market cap valuation of $ 100.54M (243.45M shares outstanding). The Outlook Therapeutics is trading on NASDAQ under the ticker sign OTLK. Outlook Therapeutics price is up
You can buy Outlook Therapeutics (OTLK) stock on eToro. For more information check our how to buy Outlook Therapeutics (OTLK) stock guide.
Description
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
Company Profile
- Full Name: Outlook Therapeutics
- Sector: Healthcare
- Website: https://www.outlooktherapeutics.com
